These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 37750695)

  • 21. Analysis of the phase 3 ESTABLISH trials of tedizolid versus linezolid in acute bacterial skin and skin structure infections.
    Shorr AF; Lodise TP; Corey GR; De Anda C; Fang E; Das AF; Prokocimer P
    Antimicrob Agents Chemother; 2015 Feb; 59(2):864-71. PubMed ID: 25421472
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetics, Safety, and Tolerability of Tedizolid Phosphate After Single-dose Administration in Healthy Korean Male Subjects.
    Kim Y; Kim A; Lee S; Choi SH; Lee DY; Song JS; Lee H; Jang IJ; Yu KS
    Clin Ther; 2017 Sep; 39(9):1849-1857. PubMed ID: 28865799
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tedizolid: a service evaluation in a large UK teaching hospital.
    York JA; Adams K; Cullen L; Delahay J; Ivan M; Lillie PJ; MacLachlan L; Barlow G
    Eur J Clin Microbiol Infect Dis; 2021 Feb; 40(2):397-405. PubMed ID: 32851509
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and tolerance of rifampicin-linezolid compared with rifampicin-cotrimoxazole combinations in prolonged oral therapy for bone and joint infections.
    Nguyen S; Pasquet A; Legout L; Beltrand E; Dubreuil L; Migaud H; Yazdanpanah Y; Senneville E
    Clin Microbiol Infect; 2009 Dec; 15(12):1163-9. PubMed ID: 19438638
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment of bone and joint infections by ceftazidime/avibactam and ceftolozane/tazobactam: a cohort study.
    Rempenault C; Pagis V; Noussair L; Berbescu S; Duran C; Bouchand F; de Laroche M; Salomon E; Nich C; Bauer T; Rottman M; Davido B; Matt M; Dinh A
    J Glob Antimicrob Resist; 2021 Jun; 25():282-286. PubMed ID: 33933698
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of linezolid for Gram-positive orthopedic infections: a prospective case series.
    Rao N; Hamilton CW
    Diagn Microbiol Infect Dis; 2007 Oct; 59(2):173-9. PubMed ID: 17574788
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Diagnosis and treatment of diabetic foot infections.
    Lipsky BA; Berendt AR; Deery HG; Embil JM; Joseph WS; Karchmer AW; LeFrock JL; Lew DP; Mader JT; Norden C; Tan JS;
    Plast Reconstr Surg; 2006 Jun; 117(7 Suppl):212S-238S. PubMed ID: 16799390
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Profile of tedizolid phosphate and its potential in the treatment of acute bacterial skin and skin structure infections.
    Hall RG; Michaels HN
    Infect Drug Resist; 2015; 8():75-82. PubMed ID: 25960671
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety of Tedizolid as Suppressive Antimicrobial Therapy for Patients With Complex Implant-Associated Bone and Joint Infection due to Multidrug-Resistant Gram-Positive Pathogens: Results From the TediSAT Cohort Study.
    Ferry T; Conrad A; Senneville E; Roux S; Dupieux-Chabert C; Dinh A; Lustig S; Goutelle S; Briot T; Pham TT; Valour F
    Open Forum Infect Dis; 2021 Jul; 8(7):ofab351. PubMed ID: 34337099
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Phase 3, Randomized, Double-Blind Study Comparing Tedizolid Phosphate and Linezolid for Treatment of Ventilated Gram-Positive Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia.
    Wunderink RG; Roquilly A; Croce M; Rodriguez Gonzalez D; Fujimi S; Butterton JR; Broyde N; Popejoy MW; Kim JY; De Anda C
    Clin Infect Dis; 2021 Aug; 73(3):e710-e718. PubMed ID: 33720350
    [TBL] [Abstract][Full Text] [Related]  

  • 32.
    Cerioli M; Batailler C; Conrad A; Roux S; Perpoint T; Becker A; Triffault-Fillit C; Lustig S; Fessy MH; Laurent F; Valour F; Chidiac C; Ferry T
    Front Med (Lausanne); 2020; 7():513242. PubMed ID: 33195289
    [No Abstract]   [Full Text] [Related]  

  • 33. Pharmacokinetic drug evaluation of tedizolid for the treatment of skin infections.
    McBride D; Krekel T; Hsueh K; Durkin MJ
    Expert Opin Drug Metab Toxicol; 2017 Mar; 13(3):331-337. PubMed ID: 28140693
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Outpatient treatment of acute bacterial skin and skin structure infections (ABSSSI) with tedizolid phosphate and linezolid in patients in the United States: Subgroup analysis of 2 randomized phase 3 trials.
    De Anda C; Anuskiewicz S; Prokocimer P; Vazquez J
    Medicine (Baltimore); 2017 Dec; 96(52):e9163. PubMed ID: 29384903
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Potential role of tedizolid phosphate in the treatment of acute bacterial skin infections.
    Urbina O; Ferrández O; Espona M; Salas E; Ferrández I; Grau S
    Drug Des Devel Ther; 2013; 7():243-65. PubMed ID: 23589680
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost of off-label antibiotic therapy for bone and joint infections: a 6-year prospective monocentric observational cohort study in a referral centre for management of complex osteo-articular infections.
    Pham TT; Mabrut E; Cochard P; Chardon P; Serrier H; Valour F; Huot L; Tod M; Leboucher G; Chidiac C; Ferry T
    J Bone Jt Infect; 2021; 6(8):337-346. PubMed ID: 34513571
    [No Abstract]   [Full Text] [Related]  

  • 37. Oral versus intravenous antibiotics for bone and joint infections: the OVIVA non-inferiority RCT.
    Scarborough M; Li HK; Rombach I; Zambellas R; Walker AS; McNally M; Atkins B; Kümin M; Lipsky BA; Hughes H; Bose D; Warren S; Mack D; Folb J; Moore E; Jenkins N; Hopkins S; Seaton RA; Hemsley C; Sandoe J; Aggarwal I; Ellis S; Sutherland R; Geue C; McMeekin N; Scarborough C; Paul J; Cooke G; Bostock J; Khatamzas E; Wong N; Brent A; Lomas J; Matthews P; Wangrangsimakul T; Gundle R; Rogers M; Taylor A; Thwaites GE; Bejon P
    Health Technol Assess; 2019 Aug; 23(38):1-92. PubMed ID: 31373271
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sulopenem: An Intravenous and Oral Penem for the Treatment of Urinary Tract Infections Due to Multidrug-Resistant Bacteria.
    Zhanel GG; Pozdirca M; Golden AR; Lawrence CK; Zelenitsky S; Berry L; Schweizer F; Bay D; Adam H; Zhanel MA; Lagacé-Wiens P; Walkty A; Irfan N; Naber K; Lynch JP; Karlowsky JA
    Drugs; 2022 Apr; 82(5):533-557. PubMed ID: 35294769
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy of cotrimoxazole (Sulfamethoxazole-Trimethoprim) as a salvage therapy for the treatment of bone and joint infections (BJIs).
    Deconinck L; Dinh A; Nich C; Tritz T; Matt M; Senard O; Bessis S; Bauer T; Rottman M; Salomon J; Bouchand F; Davido B
    PLoS One; 2019; 14(10):e0224106. PubMed ID: 31622440
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effectiveness and tolerability of prolonged linezolid treatment for chronic osteomyelitis: a retrospective study.
    Senneville E; Legout L; Valette M; Yazdanpanah Y; Beltrand E; Caillaux M; Migaud H; Mouton Y
    Clin Ther; 2006 Aug; 28(8):1155-1163. PubMed ID: 16982292
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.